NKT2152

· NiKang Therapeutics, Inc.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for NKT2152, covering 2025-11-12 to 2025-11-12. Get the full timeline:

Most recent: Clinical Trial Update: Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc) [Phase 2]

See pricing